(19)

(11)

EP 4 308 227 A1

(12)

(43) Date of publication: 24.01.2024 Bulletin 2024/04 (21) Application number: 22714692.5 (22) Date of filing: 16.03.2022

(51) International Patent Classification (IPC):  A61P 9/00(2006.01) C07D 471/04(2006.01) A61P 29/00(2006.01) A61K 31/437(2006.01) (52) Cooperative Patent Classification (CPC): C07D 471/04; A61P 9/00; A61P 29/00 (86) International application number: PCT/US2022/020474 (87) International publication number: WO 2022/197755 (22.09.2022 Gazette 2022/38)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 17.03.2021 US 202163162494 P (71) Applicant: Takeda Pharmaceutical Company Limited Osaka-shi, Osaka (JP)	(72) Inventors: PAPAIOANNOU, Nikolaos Lexington, Massachusetts 02421 (US) TRAVINS, Jeremy Mark Lexington, Massachusetts 02421 (US) FINK, Sarah Jocelyn Lexington, Massachusetts 02421 (US) ELLARD, John Mark Saffron Walden CB10 1XL (GB) RAE, Alastair Saffron Walden CB10 1XL (GB) (74) Representative: Sterling IP  Orion House Bessemer Road Welwyn Garden City AL7 1HH Welwyn Garden City AL7 1HH (GB)